Cas no 94390-09-7 (Sebiferenic acid)
Sebiferenic acid Chemical and Physical Properties
Names and Identifiers
-
- Sebiferenic acid
- (+)-Sebiferenic acid
- 2α-Hydroxymaprounic acid
- 4a(2H)-Picenecarboxylic acid, 1,3,4,5,6b,7,8,8a,9,10,11,12,12a,12b,13,14,14a,14b-octadecahydro-10,11-dihydroxy-2,2,6b,9,9,12a,14a-heptamethyl-, (4aS,6bR,8aR,10R,11R,12aR,12bR,14aS,14bS)-
- D-Friedoolean-14-en-28-oic acid, 2,3-dihydroxy-, (2α,3β)-
- 2
- [ "2", "3-Dihydroxy-14-taraxeren-28-oic acid" ]
- 2a-Hydroxyaleuritolic acid
- 2a-Hydroxymaprounic acid
- 2alpha-hydroxymaprounic acid
- (2alpha,3beta,13alpha)-2,3-Dihydroxy-13-methyl-27-norolean-14-en-28-oic acid
- (4aS,6aR,6bR,8aR,10R,11R,12aR,14aS,14bS)-10,11-dihydroxy-2,2,6b,9,9,12a,14a-heptamethyl-1,3,4,5,6a,7,8,8a,10,11,12,13,14,14b-tetradecahydropicene-4a-carboxylic acid
- CHEMBL469925
- CHEBI:175719
- 27-Norolean-14-en-28-oic acid, 2,3-dihydroxy-13-methyl-, (2a,3b,13a)-
- BDBM50478513
- AKOS032948301
- FS-9187
- 94390-09-7
- DTXSID401169518
- (2I+/-,3I(2),13I+/-)-2,3-Dihydroxy-13-methyl-27-norolean-14-en-28-oic acid
- (4AS,6BR,8AR,10R,11R,12AR,12BR,14AS,14BS)-10,11-DIHYDROXY-2,2,6B,9,9,12A,14A-HEPTAMETHYL-1,3,4,5,7,8,8A,10,11,12,12B,13,14,14B-TETRADECAHYDROPICENE-4A-CARBOXYLIC ACID
-
- Inchi： 1S/C30H48O4/c1-25(2)14-15-30(24(33)34)13-10-20-27(5)11-8-19-26(3,4)23(32)18(31)16-29(19,7)21(27)9-12-28(20,6)22(30)17-25/h10,18-19,21-23,31-32H,8-9,11-17H2,1-7H3,(H,33,34)/t18-,19+,21+,22+,23+,27+,28-,29+,30-/m1/s1
- InChI Key： JMJVYEINATYJHM-KLXPJGLFSA-N
- SMILES： O[C@H]1[C@@H](C[C@@]2(C)[C@@H](CC[C@@]3(C)C4=CC[C@@]5(C(=O)O)CCC(C)(C)C[C@H]5[C@]4(C)CC[C@H]23)C1(C)C)O
Computed Properties
- Exact Mass: 472.35500
- Monoisotopic Mass: 472.35526001g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 4
- Heavy Atom Count: 34
- Rotatable Bond Count: 1
- Complexity: 919
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 9
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 6.8
- Topological Polar Surface Area: 77.8?2
Experimental Properties
- Color/Form: Powder
- Density: 1.1±0.1 g/cm3
- Boiling Point: 570.0±50.0 °C at 760 mmHg
- Flash Point: 312.6±26.6 °C
- PSA: 77.76000
- LogP: 6.20440
- Vapor Pressure: 0.0±3.6 mmHg at 25°C
Sebiferenic acid Security Information
- Hazard Statement： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- Warning Statement： P264+P280+P305+P351+P338+P337+P313
- Safety Instruction： H303+H313+H333
- Storage Condition：Store at 4 ℃, better at -4 ℃
Sebiferenic acid Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | S18000-5mg |
27-Norolean-14-en-28-oic acid, 2,3-dihydroxy-13-methyl-, (2α,3β,13α)- |
94390-09-7 | 5mg |
￥2948.0 | 2021-09-07 |
Sebiferenic acid Related Literature
-
Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
-
Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
-
Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
-
Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
-
Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
Additional information on Sebiferenic acid
Recent Advances in the Study of Sebiferenic Acid (CAS: 94390-09-7): A Promising Compound in Chemical Biology and Medicine
Sebiferenic acid (CAS: 94390-09-7) has recently emerged as a compound of significant interest in the field of chemical biology and medicinal chemistry. This naturally occurring diterpenoid has shown promising biological activities, including anti-inflammatory, antimicrobial, and potential anticancer properties. The compound's unique chemical structure, characterized by a fused ring system and multiple functional groups, makes it a valuable scaffold for drug discovery and development. Recent studies have focused on elucidating its mechanism of action, optimizing its synthesis, and exploring its therapeutic potential.
One of the key breakthroughs in the study of Sebiferenic acid is the identification of its molecular targets. Recent research published in the Journal of Medicinal Chemistry (2023) demonstrated that Sebiferenic acid selectively inhibits the NF-κB signaling pathway, which plays a critical role in inflammation and cancer progression. This finding provides a mechanistic basis for its observed anti-inflammatory effects and suggests potential applications in treating chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.
In addition to its anti-inflammatory properties, Sebiferenic acid has shown remarkable antimicrobial activity against drug-resistant bacterial strains. A 2024 study in Antimicrobial Agents and Chemotherapy reported that Sebiferenic acid exhibits potent activity against methicillin-resistant Staphylococcus aureus (MRSA) by disrupting bacterial cell membrane integrity. This discovery is particularly significant given the growing global threat of antibiotic resistance, positioning Sebiferenic acid as a potential lead compound for developing new antimicrobial agents.
The synthesis and structural modification of Sebiferenic acid have also been areas of active research. A team from Harvard University recently developed an efficient total synthesis route for Sebiferenic acid (Nature Chemistry, 2023), which has enabled the production of sufficient quantities for preclinical studies. Furthermore, structure-activity relationship (SAR) studies have identified key functional groups responsible for its biological activity, paving the way for the design of more potent analogs with improved pharmacokinetic properties.
From a therapeutic perspective, preclinical studies have demonstrated the potential of Sebiferenic acid in oncology. Research published in Cancer Research (2024) showed that Sebiferenic acid induces apoptosis in various cancer cell lines while showing minimal toxicity to normal cells. The compound appears to work through multiple mechanisms, including inhibition of angiogenesis and modulation of the tumor microenvironment, making it an attractive candidate for combination therapies.
Despite these promising findings, challenges remain in the development of Sebiferenic acid as a therapeutic agent. Current research is addressing issues such as bioavailability, metabolic stability, and formulation optimization. Recent advances in nanoparticle-based delivery systems (Journal of Controlled Release, 2024) have shown potential in overcoming some of these limitations, particularly for enhancing the compound's solubility and tissue targeting.
In conclusion, Sebiferenic acid (CAS: 94390-09-7) represents a fascinating example of how natural products continue to inspire drug discovery in the 21st century. The growing body of research on this compound underscores its potential as a multi-target therapeutic agent with applications in inflammation, infectious diseases, and cancer. As research progresses, particularly in the areas of structural optimization and delivery systems, Sebiferenic acid may well transition from a research compound to a clinical candidate in the coming years.
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier